Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2500
Single User License Price INR 172400
Corporate User License Price USD 7500
Corporate User License Price INR 517200
Site License Price USD 5000
Site License Price INR 344800
Request a Quote

Report Title

Multiple Sclerosis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2500
Site License USD 5000
Enterprise Wide License USD 7500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Multiple Sclerosis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Multiple Sclerosis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Multiple Sclerosis-Pipeline Review, H1 2017



Executive Summary

Multiple Sclerosis-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis-Pipeline Review, H1 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 9

Multiple Sclerosis-Overview 10

Multiple Sclerosis-Therapeutics Development 11

Multiple Sclerosis-Therapeutics Assessment 48

Multiple Sclerosis-Companies Involved in Therapeutics Development 70

Multiple Sclerosis-Drug Profiles 160

Multiple Sclerosis-Dormant Projects 746

Multiple Sclerosis-Discontinued Products 763

Multiple Sclerosis-Product Development Milestones 766

Appendix 778

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Multiple Sclerosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Multiple Sclerosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Multiple Sclerosis-Pipeline by 2-BBB Medicines BV, H1 2017

Multiple Sclerosis-Pipeline by 4D Pharma PLC, H1 2017

Multiple Sclerosis-Pipeline by AB Science SA, H1 2017

Multiple Sclerosis-Pipeline by AbbVie Inc, H1 2017

Multiple Sclerosis-Pipeline by Abion Inc, H1 2017

Multiple Sclerosis-Pipeline by Ablynx NV, H1 2017

Multiple Sclerosis-Pipeline by Abzena Plc, H1 2017

Multiple Sclerosis-Pipeline by Acorda Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Actelion Ltd, H1 2017

Multiple Sclerosis-Pipeline by Adamas Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Addex Therapeutics Ltd, H1 2017

Multiple Sclerosis-Pipeline by Adhaere Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Aegis Therapeutics LLC, H1 2017

Multiple Sclerosis-Pipeline by Affectis Pharmaceuticals AG, H1 2017

Multiple Sclerosis-Pipeline by AiCuris GmbH & Co KG, H1 2017

Multiple Sclerosis-Pipeline by Alkermes Plc, H1 2017

Multiple Sclerosis-Pipeline by Allergan Plc, H1 2017

Multiple Sclerosis-Pipeline by Alpha Cancer Technologies Inc, H1 2017

Multiple Sclerosis-Pipeline by Alvotech Iceland, H1 2017

Multiple Sclerosis-Pipeline by Amarna Therapeutics BV, H1 2017

Multiple Sclerosis-Pipeline by Anavex Life Sciences Corp, H1 2017

Multiple Sclerosis-Pipeline by Antisense Therapeutics Ltd, H1 2017

Multiple Sclerosis-Pipeline by Aphios Corp, H1 2017

Multiple Sclerosis-Pipeline by Apitope International NV, H1 2017

Multiple Sclerosis-Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Multiple Sclerosis-Pipeline by Argos Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Multiple Sclerosis-Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Arven Ilac, H1 2017

Multiple Sclerosis-Pipeline by Asterias Biotherapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by AstraZeneca Plc, H1 2017

Multiple Sclerosis-Pipeline by Atara Biotherapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Athersys Inc, H1 2017

Multiple Sclerosis-Pipeline by Atlantic Bio Sci LLC, H1 2017

Multiple Sclerosis-Pipeline by Axxam SpA, H1 2017

Multiple Sclerosis-Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Multiple Sclerosis-Pipeline by BioApex sro, H1 2017

Multiple Sclerosis-Pipeline by Biocad, H1 2017

Multiple Sclerosis-Pipeline by Biocon Ltd, H1 2017

Multiple Sclerosis-Pipeline by Biogen Inc, H1 2017

Multiple Sclerosis-Pipeline by BioHealthonomics Inc, H1 2017

Multiple Sclerosis-Pipeline by Biomar Microbial Technologies, H1 2017

Multiple Sclerosis-Pipeline by Bionovis SA, H1 2017

Multiple Sclerosis-Pipeline by Bionure Farma SL, H1 2017

Multiple Sclerosis-Pipeline by Biovista Inc, H1 2017

Multiple Sclerosis-Pipeline by Bolder Biotechnology Inc, H1 2017

Multiple Sclerosis-Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Bristol-Myers Squibb Company, H1 2017

Multiple Sclerosis-Pipeline by CASI Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Catalyst Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Celgene Corp, H1 2017

Multiple Sclerosis-Pipeline by Cell Cure Neurosciences Ltd, H1 2017

Multiple Sclerosis-Pipeline by Cell2B Advanced Therapeutics SA, H1 2017

Multiple Sclerosis-Pipeline by Cinnagen Co, H1 2017

Multiple Sclerosis-Pipeline by Cognosci Inc, H1 2017

Multiple Sclerosis-Pipeline by Coherus BioSciences Inc, H1 2017

Multiple Sclerosis-Pipeline by Commence Bio Inc, H1 2017

Multiple Sclerosis-Pipeline by Compugen Ltd, H1 2017

Multiple Sclerosis-Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Multiple Sclerosis-Pipeline by Critical Outcome Technologies Inc, H1 2017

Multiple Sclerosis-Pipeline by CuraVac Inc, H1 2017

Multiple Sclerosis-Pipeline by Cyxone AB, H1 2017

Multiple Sclerosis-Pipeline by DanDrit Biotech A/S, H1 2017

Multiple Sclerosis-Pipeline by Denceptor Therapeutics Ltd, H1 2017

Multiple Sclerosis-Pipeline by Dimerix Bioscience Pty Ltd, H1 2017

Multiple Sclerosis-Pipeline by Eisai Co Ltd, H1 2017

Multiple Sclerosis-Pipeline by Eli Lilly and Company, H1 2017

Multiple Sclerosis-Pipeline by Evgen Pharma Plc, H1 2017

Multiple Sclerosis-Pipeline by Evotec AG, H1 2017

Multiple Sclerosis-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Multiple Sclerosis-Pipeline by Flex Pharma Inc, H1 2017

Multiple Sclerosis-Pipeline by Forward Pharma A/S, H1 2017

Multiple Sclerosis-Pipeline by FPRT Bio Inc, H1 2017

Multiple Sclerosis-Pipeline by Gemac SA, H1 2017

Multiple Sclerosis-Pipeline by Genervon Biopharmaceuticals LLC, H1 2017

Multiple Sclerosis-Pipeline by GeNeuro SA, H1 2017

Multiple Sclerosis-Pipeline by Genzyme Corp, H1 2017

Multiple Sclerosis-Pipeline by GlaxoSmithKline Plc, H1 2017

Multiple Sclerosis-Pipeline by Glialogix Inc, H1 2017

Multiple Sclerosis-Pipeline by Hansa Medical AB, H1 2017

Multiple Sclerosis-Pipeline by Harbor Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Humabs BioMed SA, H1 2017

Multiple Sclerosis-Pipeline by Hutchison China MediTech Ltd, H1 2017

Multiple Sclerosis-Pipeline by Immune Response BioPharma Inc, H1 2017

Multiple Sclerosis-Pipeline by Immune Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Immungenetics AG, H1 2017

Multiple Sclerosis-Pipeline by Immunwork Inc, H1 2017

Multiple Sclerosis-Pipeline by Inception Sciences Inc, H1 2017

Multiple Sclerosis-Pipeline by Innate Immunotherapeutics Ltd, H1 2017

Multiple Sclerosis-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Io Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Jyant Technologies Inc, H1 2017

Multiple Sclerosis-Pipeline by Kadimastem Ltd, H1 2017

Multiple Sclerosis-Pipeline by Kadmon Corp LLC, H1 2017

Multiple Sclerosis-Pipeline by KAHR medical Ltd, H1 2017

Multiple Sclerosis-Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Kancera AB, H1 2017

Multiple Sclerosis-Pipeline by Karo Pharma AB, H1 2017

Multiple Sclerosis-Pipeline by Karyopharm Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Multiple Sclerosis-Pipeline by KPI Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Multiple Sclerosis-Pipeline by Lead Discovery Center GmbH, H1 2017

Multiple Sclerosis-Pipeline by LFB SA, H1 2017

Multiple Sclerosis-Pipeline by Lipocure Ltd, H1 2017

Multiple Sclerosis-Pipeline by MacroGenics Inc, H1 2017

Multiple Sclerosis-Pipeline by Mapi Pharma Ltd, H1 2017

Multiple Sclerosis-Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Multiple Sclerosis-Pipeline by MedAnnex Ltd, H1 2017

Multiple Sclerosis-Pipeline by MedDay SA, H1 2017

Multiple Sclerosis-Pipeline by Medestea Research & Production SpA, H1 2017

Multiple Sclerosis-Pipeline by MedImmune LLC, H1 2017

Multiple Sclerosis-Pipeline by Merck KGaA, H1 2017

Multiple Sclerosis-Pipeline by Meta-IQ ApS, H1 2017

Multiple Sclerosis-Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Mitotech SA, H1 2017

Multiple Sclerosis-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Multiple Sclerosis-Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017

Multiple Sclerosis-Pipeline by MorphoSys AG, H1 2017

Multiple Sclerosis-Pipeline by Mount Tam Biotechnologies Inc, H1 2017

Multiple Sclerosis-Pipeline by Neuralstem Inc, H1 2017

Multiple Sclerosis-Pipeline by Neuren Pharmaceuticals Ltd, H1 2017

Multiple Sclerosis-Pipeline by Neurofx Inc, H1 2017

Multiple Sclerosis-Pipeline by Neuronax SAS, H1 2017

Multiple Sclerosis-Pipeline by New World Laboratories Inc, H1 2017

Multiple Sclerosis-Pipeline by Novartis AG, H1 2017

Multiple Sclerosis-Pipeline by Nuevolution AB, H1 2017

Multiple Sclerosis-Pipeline by Numab Innovation AG, H1 2017

Multiple Sclerosis-Pipeline by Ogeda SA, H1 2017

Multiple Sclerosis-Pipeline by Omeros Corp, H1 2017

Multiple Sclerosis-Pipeline by OncoImmune Inc, H1 2017

Multiple Sclerosis-Pipeline by Opexa Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Oryzon Genomics SA, H1 2017

Multiple Sclerosis-Pipeline by OSE Immunotherapeutics, H1 2017

Multiple Sclerosis-Pipeline by Pangen Biotech Inc., H1 2017

Multiple Sclerosis-Pipeline by Parvus Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Pfenex Inc, H1 2017

Multiple Sclerosis-Pipeline by Pfizer Inc, H1 2017

Multiple Sclerosis-Pipeline by Pharmaxis Ltd, H1 2017

Multiple Sclerosis-Pipeline by ProNoxis AB, H1 2017

Multiple Sclerosis-Pipeline by Prothena Corp Plc, H1 2017

Multiple Sclerosis-Pipeline by Quimatryx SL, H1 2017

Multiple Sclerosis-Pipeline by ReceptoPharm Inc, H1 2017

Multiple Sclerosis-Pipeline by RedHill Biopharma Ltd, H1 2017

Multiple Sclerosis-Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Regenesance BV, H1 2017

Multiple Sclerosis-Pipeline by Renovo Neural Inc, H1 2017

Multiple Sclerosis-Pipeline by Resverlogix Corp, H1 2017

Multiple Sclerosis-Pipeline by ReveraGen BioPharma Inc, H1 2017

Multiple Sclerosis-Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Rock Creek Pharmaceuticals Inc, H1 2017

Multiple Sclerosis-Pipeline by Rodos BioTarget GmbH, H1 2017

Multiple Sclerosis-Pipeline by SanBio Inc, H1 2017

Multiple Sclerosis-Pipeline by Santhera Pharmaceuticals Holding AG, H1 2017

Multiple Sclerosis-Pipeline by Sareum Holdings Plc, H1 2017

Multiple Sclerosis-Pipeline by Senju Pharmaceutical Co Ltd, H1 2017

Multiple Sclerosis-Pipeline by Sorrento Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Spherium Biomed SL, H1 2017

Multiple Sclerosis-Pipeline by Symic Biomedical Inc, H1 2017

Multiple Sclerosis-Pipeline by Synthon Holdings BV, H1 2017

Multiple Sclerosis-Pipeline by Teikoku Pharma USA Inc, H1 2017

Multiple Sclerosis-Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Multiple Sclerosis-Pipeline by TikoMed AB, H1 2017

Multiple Sclerosis-Pipeline by Tiziana Life Sciences Plc, H1 2017

Multiple Sclerosis-Pipeline by Toleranzia AB, H1 2017

Multiple Sclerosis-Pipeline by Topas Therapeutics GmbH, H1 2017

Multiple Sclerosis-Pipeline by TxCell SA, H1 2017

Multiple Sclerosis-Pipeline by Vaccinex Inc, H1 2017

Multiple Sclerosis-Pipeline by Vakzine Projekt Management GmbH, H1 2017

Multiple Sclerosis-Pipeline by Vicore Pharma AB, H1 2017

Multiple Sclerosis-Pipeline by viDA Therapeutics Inc, H1 2017

Multiple Sclerosis-Pipeline by Virogenomics BioDevelopment Inc, H1 2017

Multiple Sclerosis-Pipeline by VivaCell Biotechnology Espana SL, H1 2017

Multiple Sclerosis-Pipeline by Xenetic Biosciences Inc, H1 2017

Multiple Sclerosis-Pipeline by XL-protein GmbH, H1 2017

Multiple Sclerosis-Pipeline by Yungjin Pharm Co Ltd, H1 2017

Multiple Sclerosis-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..3), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..4), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..5), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..6), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..7), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..8), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..9), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..10), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..11), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..12), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..13), H1 2017

Multiple Sclerosis-Dormant Projects, H1 2017 (Contd..14), H1 2017

Multiple Sclerosis-Discontinued Products, H1 2017

Multiple Sclerosis-Discontinued Products, H1 2017 (Contd..1), H1 2017

Multiple Sclerosis-Discontinued Products, H1 2017 (Contd..2), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

2-BBB Medicines BV

4D Pharma PLC

AB Science SA

AbbVie Inc

Abion Inc

Ablynx NV

Abzena Plc

Acorda Therapeutics Inc

Actelion Ltd

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Adhaere Pharmaceuticals Inc

Aegis Therapeutics LLC

Affectis Pharmaceuticals AG

AiCuris GmbH & Co KG

Alkermes Plc

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech Iceland

Amarna Therapeutics BV

Anavex Life Sciences Corp

Antisense Therapeutics Ltd

Aphios Corp

Apitope International NV

ARA Healthcare Pvt Ltd

Argos Therapeutics Inc

Arrien Pharmaceuticals LLC

Artielle ImmunoTherapeutics Inc

Arven Ilac

Asterias Biotherapeutics Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athersys Inc

Atlantic Bio Sci LLC

Axxam SpA

Bio-Cancer Treatment International Ltd

BioApex sro

Biocad

Biocon Ltd

Biogen Inc

BioHealthonomics Inc

Biomar Microbial Technologies

Bionovis SA

Bionure Farma SL

Biovista Inc

Bolder Biotechnology Inc

BrainStorm Cell Therapeutics Inc

Bristol-Myers Squibb Company

CASI Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Celgene Corp

Cell Cure Neurosciences Ltd

Cell2B Advanced Therapeutics SA

Cinnagen Co

Cognosci Inc

Coherus BioSciences Inc

Commence Bio Inc

Compugen Ltd

Connexios Life Sciences Pvt Ltd

Critical Outcome Technologies Inc

CuraVac Inc

Cyxone AB

DanDrit Biotech A/S

Denceptor Therapeutics Ltd

Dimerix Bioscience Pty Ltd

Eisai Co Ltd

Eli Lilly and Company

Evgen Pharma Plc

Evotec AG

F. Hoffmann-La Roche Ltd

Flex Pharma Inc

Forward Pharma A/S

FPRT Bio Inc

Gemac SA

Genervon Biopharmaceuticals LLC

GeNeuro SA

Genzyme Corp

GlaxoSmithKline Plc

Glialogix Inc

Hansa Medical AB

Harbor Therapeutics Inc

Humabs BioMed SA

Hutchison China MediTech Ltd

Immune Response BioPharma Inc

Immune Therapeutics Inc

Immungenetics AG

Immunwork Inc

Inception Sciences Inc

Innate Immunotherapeutics Ltd

Inovio Pharmaceuticals Inc

Io Therapeutics Inc

Jyant Technologies Inc

Kadimastem Ltd

Kadmon Corp LLC

KAHR medical Ltd

KaloBios Pharmaceuticals Inc

Kancera AB

Karo Pharma AB

Karyopharm Therapeutics Inc

Kissei Pharmaceutical Co Ltd

KPI Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Lead Discovery Center GmbH

LFB SA

Lipocure Ltd

MacroGenics Inc

Mapi Pharma Ltd

Marathon Pharmaceuticals LLC

MedAnnex Ltd

MedDay SA

Medestea Research & Production SpA

MedImmune LLC

Merck KGaA

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mochida Pharmaceutical Co Ltd

MorphoSys AG

Mount Tam Biotechnologies Inc

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

Neuronax SAS

New World Laboratories Inc

Novartis AG

Nuevolution AB

Numab Innovation AG

Ogeda SA

Omeros Corp

OncoImmune Inc

Opexa Therapeutics Inc

Oryzon Genomics SA

OSE Immunotherapeutics

Pangen Biotech Inc.

Parvus Therapeutics Inc

Pfenex Inc

Pfizer Inc

Pharmaxis Ltd

ProNoxis AB

Prothena Corp Plc

Quimatryx SL

ReceptoPharm Inc

RedHill Biopharma Ltd

RegeneRx Biopharmaceuticals Inc

Regenesance BV

Renovo Neural Inc

Resverlogix Corp

ReveraGen BioPharma Inc

Rigel Pharmaceuticals Inc

Rock Creek Pharmaceuticals Inc

Rodos BioTarget GmbH

SanBio Inc

Santhera Pharmaceuticals Holding AG

Sareum Holdings Plc

Senju Pharmaceutical Co Ltd

Sorrento Therapeutics Inc

Spherium Biomed SL

Symic Biomedical Inc

Synthon Holdings BV

Teikoku Pharma USA Inc

Teva Pharmaceutical Industries Ltd

TikoMed AB

Tiziana Life Sciences Plc

Toleranzia AB

Topas Therapeutics GmbH

TxCell SA

Vaccinex Inc

Vakzine Projekt Management GmbH

Vicore Pharma AB

viDA Therapeutics Inc

Virogenomics BioDevelopment Inc

VivaCell Biotechnology Espana SL

Xenetic Biosciences Inc

XL-protein GmbH

Yungjin Pharm Co Ltd

Zydus Cadila Healthcare Ltd

Multiple Sclerosis Therapeutic Products under Development, Key Players in Multiple Sclerosis Therapeutics, Multiple Sclerosis Pipeline Overview, Multiple Sclerosis Pipeline, Multiple Sclerosis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person